SGMO 
LLY has entered into a license agreement with Eli Lilly $LLY. The deal, announced today, includes an $18 million upfront license fee paid to Sangamo, with the potential for the California-based biotech to receive up to $1.4 billion in additional fees and milestone payments for five potential disease targets. businesswire.com/news/home/20250403023818/en/Sangamo-Therapeutics-Announces-Capsid-License-Agreement-With-Lilly-to-Deliver-Genomic-Medicines-for-Diseases-of-the-Central-Nervous-System